-
Juno Therapeutics' Hold Is 'More Impactful To Sentiment Than Estimates'
Wednesday, November 23, 2016 - 3:17pm | 235Read More...Dane Leone of BTIG remains Neutral on Juno Therapeutics Inc (NASDAQ: JUNO), which voluntarily placed on hold a mid-stage clinical trial dubbed ROCKET of JCAR015 tested in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia. The company’s move follows two patient...
-
BTIG Is No Longer Selling Juno Therapeutics Stock
Friday, November 4, 2016 - 9:45am | 263Read More...BTIG’s Dane Leone has upgraded Juno Therapeutics Inc (NASDAQ: JUNO) to Neutral from Sell, as the shares have hit his target price and the ASH abstract release showed similar response rates for the company’s JCAR017 versus Kite Pharma Inc (NASDAQ: KITE)’s KTE-C19 in patients with...
-
Favorable FDA Pathway Should Keep Bluebird's Clinical Studies Flying Straight
Friday, October 14, 2016 - 8:21am | 293Read More...During its R&D day, bluebird bio Inc (NASDAQ: BLUE) provided insight into the new manufacturing process for LentiGlobin and an update on the design of the Beta-thalassemia pivotal studies. The design should support LentiGlobin’s commercial launch for “essentially the entire...
-
Illumina's Poor Streak Is A Sign Of Market Saturation
Tuesday, October 11, 2016 - 9:16am | 337Read More...Illumina, Inc. (NASDAQ: ILMN) preannounced Q3 revenues significant below expectations, marking the fourth miss in the past six quarters. Internal growth forecasts seem to be “failing to accurately reflect market demand,” BTIG’s Dane Leone said in a report. He maintained a...
-
Sell Juno Therapeutics: BTIG Says It's Trailing The Competition
Wednesday, August 31, 2016 - 9:19am | 307Read More...BTIG’s Dane Leone believes that while Juno Therapeutics Inc (NASDAQ: JUNO) has the most robust CD19 CAR T datasets among its competitors, it is trailing in terms of timelines for regulatory approval and commercialization. Leone initiated coverage of the company with a Sell rating and price...
-
BTIG Is 'Generally Skeptical' On Kite Pharma Expectations
Wednesday, August 31, 2016 - 9:17am | 429Read More...BTIG has started coverage of Kite Pharma Inc (NASDAQ: KITE) with a Neutral rating, as it is skeptical over current investor expectations for the CD19 CAR T market, given the limited datasets and potential competition from CD19 bi-specific antibodies. Kite is pursuing Chimeric Antigen Receptor T-...
-
BTIG Research Upgrades Alere To Buy, Says 10-K Filing Offers 'Fundamental Opportunity'
Tuesday, August 9, 2016 - 8:15am | 309Read More...Alere Inc’s (NYSE: ALR) 10K offered financial clarity, alleviating concerns related to gaps in the company’s current model, BTIG Research’s Dane Leone said in a report. He upgraded the rating on the company from Neutral to Buy, while establishing a new price target of $48....
-
Celgene Could Achieve 2020 Targets, BTIG Upgrades To Buy
Thursday, August 4, 2016 - 8:17am | 285Read More...Although Celgene Corporation’s (NASDAQ: CELG) financial targets for 2020 are higher than consensus expectations, the company may be able to achieve them through new commercial products, label expansion and M&A, BTIG’s Dane Leone said in a report. He upgraded the rating on the...
-
Celgene Downgraded To Netural As Company Might Be Relying Too Heavily On Revlimid
Wednesday, June 1, 2016 - 3:02pm | 191Read More...BTIG's Dane Leone downgraded Celgene Corporation (NASDAQ: CELG) from Buy to Neutral. Leone noted Celgene has made multiple innovate early stage investments "but…unsure of upside to current consensus estimates." The majority of the company's sales growth is dependent on...
-
Under-Promising, Over-Delivering: Has Agilent's Management Gained Credibility?
Tuesday, May 17, 2016 - 7:55am | 321Read More...Agilent Technologies Inc (NYSE: A) reported its FY2Q16 results broadly ahead of expectations. BTIG’s Dane Leone reiterated a Buy rating for the company, with a price target of $50. The analyst commented that management would begin gaining credibility for “under-promising and over-...
-
BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts
Thursday, May 5, 2016 - 3:07pm | 264Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) were trading lower by 5 percent mid-Thursday afternoon after the company reported its first-quarter results. Bluebird bio said that it lost $1.52 per share on revenue of $1.499 million during the quarter. Wall Street analysts were expecting the company to...
-
BTIG Downgrades Bruker, Still Likes Long-Term Story
Thursday, May 5, 2016 - 9:31am | 270Read More...BTIG has downgraded Bruker Corporation (NASDAQ: BRKR) to Neutral from Outperform, saying the "margin story continues to play out but [we] are hesitant to expect upside to its current organic growth forecasts this early in 2016." The scientific equipment maker reported first quarter EPS of $0.21,...
-
BTIG Starts MacroGenics At Buy, Sees 63% Upside
Thursday, April 7, 2016 - 5:29pm | 196Read More...BTIG Research's Dane Leone initiated coverage on a cancer treatment and infectious disease biotech company Thursday afternoon, MacroGenics Inc (NASDAQ: MGNX). The analyst set a Buy rating and $35 price target, representing potential upside of about 63 percent from the stock's close....
-
UPDATE: BTIG Initiates Coverage On Thermo Fisher Scientific Inc.
Friday, October 3, 2014 - 9:02am | 158Read More...BTIG initiated a Neutral rating on Thermo Fisher Scientific Inc. (NYSE: TMO) with an expected trading range of $110 to $130. Analyst Dane Leone claimed that while the company is well run and “can sustainably expand sales above end‐market growth rates,” he thinks that “market...
-
UPDATE: BTIG Initiates Coverage On Affymetrix, Inc.
Friday, October 3, 2014 - 8:56am | 140Read More...In a note released Thursday, BTIG analyst Dane Leone initiated coverage of Affymetrix, Inc. (NASDAQ: AFFX) with a Neutral rating and a near-term trading range of $7.50 to $10. Leone commented, "In our view, solid execution by the management team has moved AFFX from being a ‘...
